Stories & Trends in Respiratory Nasal Sampling

New antiviral evidence revealed baloxavir (Xofluza) as the superior flu treatment to oseltamivir (Tamiflu), and this emerging antiviral treatment strategy amplifies the consequences of delayed diagnoses. What does this mean for patients and healthcare systems, and how does smarter nasal sampling play a larger role than once thought?

In his latest article for MedCity News, Dr. Wadman explains why delivering a proper URI diagnosis within the first 96 hours after symptom onset is critical for stronger healthcare system operations and patient outcomes. That pivotal window guides everything that follows, from individual treatment decisions to large-scale outbreak control.

Patient experience is one of the most powerful drivers of a healthcare system’s financial, reputational and operational resilience. Discover the often-overlooked downstream impact of intrusive nasal swabs, and why evolved nasal lavage is the more comfortable, sensitive and ultimately cost-effective solution for modern healthcare systems.

Dr. Lorenzo was recently featured in an in-depth Q&A with Authority Magazine to give an inside look into his upbringing, education, mentorship and leadership path. Discover the origins that shaped his mission to strengthen diagnostic preparedness and public health through better sampling methods like MicroWash.

The MicroWash nasal lavage device gives laboratories a more efficient collection method that supports high-sensitivity results and smooth integration into existing PCR processes. Here are the top five questions we receive from lab professionals, answered.

With 90 inventions to his credit, two successful startups, two U.S. patents secured and another five pending, Dr. Nguyen claimed the Faculty Entrepreneur distinction at UNeMed’s Research Innovation Awards and was welcomed to its Innovation Ambassadors cohort.

Treating seasonal spikes as isolated crises traps healthcare systems in a reactive cycle rather than a proactive one. Explore how learnings from recent “tripledemics” of flu, RSV and COVID-19 can inform a more sustainable sampling model for URI management.

Dr. Wadman joins PSQH: The Podcast to discuss how challenges he personally faced with nasal swab sampling at the start of the pandemic inspired new innovations in evolved nasal lavage. He highlights how MicroWash delivers more comfortable and sensitive specimens to support future outbreak containment. Tune in to the episode.

Patient discomfort from nasal swabs drives testing avoidance, undermining early diagnosis, treatment and outbreak control for URIs. Evolved nasal lavage offers a safer, more tolerable alternative that delivers higher-sensitivity samples, simplifies clinical use and strengthens public health readiness. MicroWash is setting the new collection standard.

Where and how we collect pathogen-containing material for URI testing can make the difference between a confirmed infection and a missed case. Dive into the science behind why evolved nasal lavage solutions like MicroWash produce higher-sensitivity samples compared to the swab — and why that matters for more effective treatment and outbreak response.